News
Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...
One company remains at the forefront of the AI frenzy, whereas the other has seen insiders dive in post-earnings.
Eli Lilly delivered above-consensus results in the second quarter, surpassing Wall Street’s revenue and non-GAAP profit ...
Trump administration demands lower prices in the U.S., forcing the pharmaceutical company to raise them in other markets ...
Texas is seeking more than $1 million from Eli Lilly in a lawsuit accusing the drugmaker of persuading physicians to prescribe its medications, including GLP-1s such as Mounjaro and Zepbound, through ...
GLP-1 receptor agonists like semaglutide and the dual GIP/GLP-1 agonist tirzepatide mimic naturally occurring hormones that regulate blood sugar, appetite, and digestion. GLP-1 (glucagon-like ...
2h
Everyday Health on MSNFDA Raises Safety Concerns About Compounded GLP-1 Weight Loss Drugs
The agency shared information from reports by users of compounded semaglutide and tirzepatide who have experienced health ...
No blanket recommendation can be made for SGLT2 inhibitors and GLP-1 receptor agonists in adults with type 2 diabetes (T2D) without considering cardiovascular and kidney risks, according to a BMJ ...
2h
Bizcommunity.com on MSNDanish weight-loss drug Wegovy debuts in South Africa, challenging Eli Lilly
Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa, marking its debut in Africa and stepping up competition with Eli Lilly's Mounjaro launched in the country eight ...
7hon MSN
Eli Lilly Says It Will Raise European Prices of its Medicines as Trump Pushes for U.S. Price Cuts
Late last month, President Donald Trump issued letters to Lilly CEO David Ricks and to the CEOs of roughly a dozen other ...
More than 1 in 4 adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results